A Covid-19 antibody treatment from Vir and Glaxo is no longer authorized in the U.S. because the therapy is unlikely to work against the now-dominant omicron BA.2 subvariant https://t.co/9prLSNhPnI— Bloomberg (@business) April 5, 2022
(SocialLY brings you all the latest breaking news, fact checks and information from social media world, including Twitter (X), Instagram and Youtube. The above post contains publicly available embedded media, directly from the user's social media account and the views appearing in the social media post do not reflect the opinions of LatestLY.)













Quickly


